|
|
Volumn 209, Issue , 2016, Pages 15-16
|
|
Pathogen-driven treatment strategy in new onset dilated cardiomyopathy. Impact on ventricular function and clinical outcome
a
b
|
|
Author keywords
Dilated cardiomyopathy; Endomyocardial biopsy; Infective agents; Prognosis; Specific antimicrobial treatment
|
|
Indexed keywords
ACICLOVIR;
DOXYCYCLINE;
VALGANCICLOVIR;
ANTIINFECTIVE AGENT;
ADULT;
ARTICLE;
CHLAMYDIASIS;
CLINICAL EFFECTIVENESS;
CONGESTIVE CARDIOMYOPATHY;
CONTROLLED STUDY;
CYTOMEGALOVIRUS INFECTION;
EPSTEIN BARR VIRUS INFECTION;
FEMALE;
HEART LEFT VENTRICLE EJECTION FRACTION;
HEART VENTRICLE FUNCTION;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
TERTIARY CARE CENTER;
CARDIOMYOPATHY, DILATED;
CHLAMYDIA;
DRUG EFFECTS;
FOLLOW UP;
HEART STROKE VOLUME;
HUMAN PARVOVIRUS B19;
ISOLATION AND PURIFICATION;
MICROBIOLOGY;
MIDDLE AGED;
PHYSIOLOGY;
PROSPECTIVE STUDY;
TREATMENT OUTCOME;
ADULT;
ANTI-INFECTIVE AGENTS;
CARDIOMYOPATHY, DILATED;
CHLAMYDIA;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
MALE;
MIDDLE AGED;
PARVOVIRUS B19, HUMAN;
PROSPECTIVE STUDIES;
STROKE VOLUME;
TREATMENT OUTCOME;
VENTRICULAR FUNCTION;
|
|
EID: 84961675238
PISSN: 01675273
EISSN: 18741754
Source Type: Journal
DOI: 10.1016/j.ijcard.2016.02.032 Document Type: Article |
|
Times cited : (5)
|
|
References (4)
|
